SenesTech (SNES) vs. Syngenta (SYT) Head-To-Head Review

SenesTech (NASDAQ: SNES) and Syngenta (NYSE:SYT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Analyst Recommendations

How to Become a New Pot Stock Millionaire

This is a summary of recent recommendations for SenesTech and Syngenta, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SenesTech 0 0 2 0 3.00
Syngenta 0 0 0 0 N/A

SenesTech presently has a consensus target price of $8.50, indicating a potential upside of 1,708.51%. Given SenesTech’s higher probable upside, equities research analysts clearly believe SenesTech is more favorable than Syngenta.

Earnings and Valuation

This table compares SenesTech and Syngenta’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SenesTech $50,000.00 155.19 -$12.28 million ($1.12) -0.42
Syngenta $12.79 billion 3.36 $1.18 billion $3.41 27.24

Syngenta has higher revenue and earnings than SenesTech. SenesTech is trading at a lower price-to-earnings ratio than Syngenta, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

22.4% of SenesTech shares are owned by institutional investors. Comparatively, 0.2% of Syngenta shares are owned by institutional investors. 27.4% of SenesTech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

SenesTech has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, Syngenta has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500.

Profitability

This table compares SenesTech and Syngenta’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SenesTech -23,626.92% -194.40% -150.29%
Syngenta N/A N/A N/A

Summary

Syngenta beats SenesTech on 7 of the 12 factors compared between the two stocks.

About SenesTech

SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. The company focuses on commercializing ContraPest, a fertility control product for use in controlling rat populations. It is also developing a pipeline of fertility control and animal health products, including plant-based fertility control, feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment. The company was founded in 2004 and is headquartered in Flagstaff, Arizona.

About Syngenta

Syngenta AG (Syngenta) is an agribusiness company. The Company operates in the crop protection and seeds business, which is involved in the discovery, development, manufacture and marketing of a range of products designed to improve crop yields and food quality, and in the lawn and garden business, which provides professional growers and consumers with flowers, turf and landscape, and professional pest management products. It operates in four geographic regions: Europe, Africa and Middle East; North America; Latin America, and Asia Pacific. It also operates the Crop Protection and Seeds businesses, and the global Lawn and Garden business. Syngenta has a range of selective herbicides that control grasses and broad-leaved weeds and are applicable to various crops. Syngenta has a range of Fungicides that prevent and cure fungal plant diseases. In addition, Syngenta has a range of biologicals into its portfolio in various countries, including the brands QUANTIS, ISABION and SAKALIA.

Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply